The weekly litigation news digest is live. Subscribe now
An Anhydrous Pharmaceutical Composition For Maintenance Treatment Of Psoriasis - EP4041186
The patent EP4041186 was granted to LEO Pharma on May 22, 2024. The application was originally filed on Oct 7, 2020 under application number EP20789063A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP4041186
- Application Number
- EP20789063A
- Filing Date
- Oct 7, 2020
- Status
- Granted And Under Opposition
- Apr 19, 2024
- Publication Date
- May 22, 2024
- External Links
- Slate, Register, Google Patents
Patent Summary
An anhydrous topical pharmaceutical composition for maintaining psoriasis remission by treating psoriasis patients when they are in remission following an initial course of therapy. The composition contains calcipotriol, betamethasone, petrolatum, and a propellant. The patients apply the composition biweekly when they are in remission to prevent relapses and prolong remission duration compared to not using the composition. The biweekly maintenance treatment reduces relapse rate, time to first relapse, and improves remission duration versus no maintenance therapy.
Patent Family
Patent Oppositions (3)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (4) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents